This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Guo, H. Articles by Wang, B. Search for Related Content PubMed PubMed Citation Articles by Guo, H. Articles by Wang, B.

Disruption of EphA2 Receptor Tyrosine Kinase Leads to Increased Susceptibility to Carcinogenesis in Mouse Skin

¹ Rammelkamp Center for Research and Department of Pharmacology and Comprehensive Cancer Center; ² Department of Dermatology, University Hospital of Cleveland, Case Western Reserve University, Cleveland, Ohio; and ³ Department of Pathology, Cardinal Bernardin Cancer Center, Loyola University Medical Center, Maywood, Illinois

Requests for reprints: Bingcheng Wang, Rammelkamp Center for Research, Case Western Reserve University, R421, 2500 MetroHealth Drive, Cleveland, OH 44109. Phone: 216-778-4256; Fax: 216-778-4321; E-mail: bxw14{at}case.edu.

EphA2 receptor tyrosine kinase is frequently overexpressed in different human cancers, suggesting that it may promote tumor development and progression. However, evidence also exists that EphA2 may possess antitumorigenic properties, raising a critical question on the role of EphA2 kinase in tumorigenesis in vivo. We report here that deletion of EphA2 in mouse led to markedly enhanced susceptibility to 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (DMBA/TPA) two-stage skin carcinogenesis. EphA2-null mice developed skin tumors with an increased frequency and shortened latency. Moreover, tumors in homozygous knockout mice grew faster and were twice as likely to show invasive malignant progression. Haploinsufficiency of EphA2 caused an intermediate phenotype in tumor development but had little effects on invasive progression. EphA2 and ephrin-A1 exhibited compartmentalized expression pattern in mouse skin that localized EphA2/ephrin-A1 interactions to the basal layer of epidermis, which was disrupted in tumors. Loss of EphA2 increased tumor cell proliferation, whereas apoptosis was not affected. In vitro, treatment of primary keratinocytes from wild-type mice with ephrin-A1 suppressed cell proliferation and inhibited extracellular signal-regulated kinase 1/2 (ERK1/2) activities. Both effects were abolished in EphA2-null keratinocytes, suggesting that loss of ERK inhibition by EphA2 may be one of the contributing mechanisms for increased tumor susceptibility. Interestingly, despite its tumor suppressive function, EphA2 was overexpressed in skin tumors compared with surrounding normal skin in wild-type mice, similar to the observations in human cancers. EphA2 overexpression may represent a compensatory feedback mechanism during tumorigenesis. Together, these results show that EphA2 is a novel tumor suppressor gene in mammalian skin. (Cancer Res 2006; 66(14): 7050-8)

This article has been cited by other articles:

				T. Okazaki, A. Ni, P. Baluk, O. A. Ayeni, J. Kearley, A. J. Coyle, A. Humbles, and D. M. McDonald Capillary Defects and Exaggerated Inflammatory Response in the Airways of EphA2-Deficient Mice Am. J. Pathol., June 1, 2009; 174(6): 2388 - 2399. [Abstract] [Full Text] [PDF]

				M. L. Taddei, M. Parri, A. Angelucci, B. Onnis, F. Bianchini, E. Giannoni, G. Raugei, L. Calorini, N. Rucci, A. Teti, et al. Kinase-Dependent and -Independent Roles of EphA2 in the Regulation of Prostate Cancer Invasion and Metastasis Am. J. Pathol., April 1, 2009; 174(4): 1492 - 1503. [Abstract] [Full Text] [PDF]

				K. Miura, J.-M. Nam, C. Kojima, N. Mochizuki, and H. Sabe EphA2 Engages Git1 to Suppress Arf6 Activity Modulating Epithelial Cell-Cell Contacts Mol. Biol. Cell, April 1, 2009; 20(7): 1949 - 1959. [Abstract] [Full Text] [PDF]

				G. Zhang, C.-N. Njauw, J. M. Park, C. Naruse, M. Asano, and H. Tsao EphA2 Is an Essential Mediator of UV Radiation-Induced Apoptosis Cancer Res., March 15, 2008; 68(6): 1691 - 1696. [Abstract] [Full Text] [PDF]

				N. K. Noren and E. B. Pasquale Paradoxes of the EphB4 Receptor in Cancer Cancer Res., May 1, 2007; 67(9): 3994 - 3997. [Abstract] [Full Text] [PDF]

				A. B. Larsen, M. W. Pedersen, M.-T. Stockhausen, M. V. Grandal, B. v. Deurs, and H. S. Poulsen Activation of the EGFR Gene Target EphA2 Inhibits Epidermal Growth Factor-Induced Cancer Cell Motility Mol. Cancer Res., March 1, 2007; 5(3): 283 - 293. [Abstract] [Full Text] [PDF]